Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI could spot breast cancer on routine chest CTs, no extra test needed

NCT ID NCT07557654

Diagnosis Sponsor: Fudan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether artificial intelligence can help detect breast cancer using standard chest CT scans that don't require a special dye. Researchers will compare the AI's accuracy to mammograms and breast MRIs in 5,000 women. The goal is to see if this approach could offer a convenient, opportunistic screening option during routine chest imaging.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 5,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of female patients undergoing non-contrast chest CT scans for any clinical indication at participating institutions, with or without breast lesions detected on CT. For participants included in the comparative analysis, at least one additional breast imaging modality (mammography and/or breast MRI) must have been performed within three months of the non-contrast chest CT examination and without any intervening clinical events.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Female patients who have undergone non-contrast chest CT examination; 2. Participants included in the comparative analysis must have undergone at least one comparator imaging modality (mammography and/or breast MRI); 3. If a breast lesion is detected, it must be confirmed by pathology or clinical follow-up at least 12 months; 4. No prior systemic or local therapy before imaging examinations; 5. Imaging data are complete and of sufficient quality for analysis. Exclusion Criteria: 1. History of other malignancies with potential impact on breast imaging interpretation; 2. Participants with suspected malignant breast lesions but no confirmation; 3. Prior radiotherapy, chemotherapy, or immunotherapy before imaging examinations; 4. Imaging data that are incomplete, of poor quality, or contain significant artifacts preventing reliable analysis; 5. Time interval between non-contrast chest CT and comparator imaging modalities exceeding three months, or with clinical events occurring between examinations that may alter lesion status.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.